IL15 and cancer: On April 22, 2024, the IL15 super-agonist N-803 (Anktiva) developed by ImmunityBio was approved by the FDA for use in combination with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.